As global markets navigate geopolitical tensions and economic uncertainties, Asian equities have shown resilience, with some indices maintaining stability amid fluctuating conditions. In this environment, identifying undervalued stocks can offer opportunities for investors seeking to capitalize on potential market inefficiencies. Recognizing a good stock often involves assessing its intrinsic value relative to its current price, especially in regions like Asia where emerging economic trends may present unique investment prospects.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
Name
Current Price
Fair Value (Est)
Discount (Est)
SHIFT (TSE:3697)
¥656.20
¥1288.98
49.1%
Shenzhen Yanmade Technology (SHSE:688312)
CN¥70.07
CN¥138.86
49.5%
Rayhoo Motor DiesLtd (SZSE:002997)
CN¥29.98
CN¥58.21
48.5%
Premium Group (TSE:7199)
¥1842.00
¥3672.79
49.8%
Paradise Entertainment (SEHK:1180)
HK$0.70
HK$1.38
49.4%
NexTone (TSE:7094)
¥1467.00
¥2898.17
49.4%
JAC Recruitment (TSE:2124)
¥862.00
¥1694.20
49.1%
Inner Mongolia Xingye Silver & Tin Mining (SZSE:000426)
Let’s review some notable picks from our screened stocks.
Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products in China, the United States, and internationally, with a market cap of approximately HK$156.17 billion.
Operations: The company’s revenue is primarily derived from its biotechnology segment, which generated CN¥13.04 billion.
Estimated Discount To Fair Value: 31.8%
Innovent Biologics appears undervalued based on cash flow analysis, trading at HK$90, below its estimated future cash flow value of HK$131.92. Analysts forecast significant earnings growth of 30.8% annually, surpassing the Hong Kong market average. Recent financials show a shift from a net loss to a CNY 813.57 million profit in 2025, alongside substantial revenue growth to CNY 13 billion. The company is advancing innovative treatments like IBI3055 and expanding its collaboration with Eli Lilly for global development.
SEHK:1801 Discounted Cash Flow as at Apr 2026
Overview: Akeso, Inc. is a biopharmaceutical company involved in the research, development, manufacture, and commercialization of antibody drugs globally, with a market cap of approximately HK$125.09 billion.
Operations: The company generates CN¥3.06 billion from its activities in the research, development, production, and sale of biopharmaceutical products.
Estimated Discount To Fair Value: 25.2%
Akeso is trading at HK$135.8, significantly below its estimated future cash flow value of HK$181.63, suggesting it may be undervalued based on cash flows. The company’s earnings are projected to grow 46.81% annually, with revenue expected to expand by 29.1% per year, outpacing the Hong Kong market average. Recent advancements in its bispecific antibodies like ivonescimab and cadonilimab highlight Akeso’s strong position in innovative oncology treatments despite current net losses increasing to CNY 1.11 billion in 2025 from the previous year.
SEHK:9926 Discounted Cash Flow as at Apr 2026
Overview: Elite Material Co., Ltd. manufactures and sells copper clad laminates, electronic-industrial specialty chemicals, raw materials, and electronic components in Taiwan, China, and internationally with a market cap of NT$1.63 trillion.
Operations: The company’s revenue is derived from the manufacturing and sales of copper clad laminates, electronic-industrial specialty chemicals and raw materials, as well as electronic components across Taiwan, China, and international markets.
Estimated Discount To Fair Value: 15.2%
Elite Material’s recent earnings report shows strong financial performance with first-quarter sales of TWD 33.07 billion and net income of TWD 5.34 billion, reflecting significant growth from the previous year. Despite high share price volatility, the stock trades at NT$4,545, below its future cash flow value of NT$5,361.89. Forecasts indicate robust annual earnings growth of 47.44% and revenue expansion at 42%, outpacing Taiwan’s market averages, underscoring potential undervaluation based on cash flows.
TWSE:2383 Discounted Cash Flow as at Apr 2026
Make It Happen
Searching for a Fresh Perspective?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:1801 SEHK:9926 and TWSE:2383.
This article was originally published by Simply Wall St.
Leave a comment